Madrigal Pharmaceuticals, Inc. (MDGL) est une société cotée en bourse dans le Santé secteur, opérant dans le Biotechnologie secteur d'activité. Le siège social de l'entreprise est situé à West Conshohocken, PA, United States. Le PDG actuel est William J. Sibold.
MDGL a date d'introduction en bourse 2007-02-06, 528 employés à temps plein, cotée sur le NASDAQ Global Select, une capitalisation boursière de $12.04B.
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing innovative therapeutic candidates for cardiovascular, metabolic, and liver diseases. The company's lead product, resmetirom, is a liver-directed selective thyroid hormone receptor-ß agonist currently in Phase III clinical trials for treating non-alcoholic steatohepatitis. Madrigal is also advancing MGL-3745 as a backup compound and has established a research, development, and commercialization partnership with Hoffmann-La Roche. Headquartered in West Conshohocken, Pennsylvania, the company is positioned to address significant unmet medical needs in serious metabolic and hepatic diseases.
